Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans

Arginine-vasopressin (AVP) deficiency (AVP-D) is caused by hypothalamic-pituitary damage of vasopressinergic neurons leading to polyuria and polydipsia. Diagnostic tests for AVP-D are limited by low accuracy and/or tolerability. Kisspeptin (KP) stimulates AVP release in animals, but no study has investigated KP as a provocative test for AVP-D in humans. We investigated circulating AVP levels in response to intravenous (IV) KP in adults. We also explored sex differences in AVP response to KP. Twelve healthy adults (50% female) received an IV KP bolus. Serum AVP was measured pre- and 10, 20, 40, and 60 min post-KP. AVP levels were higher in males at all time points (p = .028) and did not change in response to KP. KP did not stimulate AVP, possibly due to dose, administration route, or cross-species differences in the AVP system. Our study does not support IV KP bolus of 0.24 nmol/kg as a provocative test for AVP-D. CLINICAL TRIAL REGISTRATION: Our study was registered on ClinicalTrials.gov (NCT00914823).

Authors

Institutions

Publication Details

Journal
Journal of Neuroendocrinology
Published
2025-11-22
DOI
https://doi.org/10.1111/jne.70114
Citations
1
Primary Topic
Neuroendocrine regulation and behavior
Type
article
Field-Weighted Citation Impact
2.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans

Francesca Galbiati, Anna Aulinas, Karen Klahr Miller, John M. Davis et al.
1 citations
Journal of Neuroendocrinology
Neuroendocrine regulation and behavior
2.44
article

Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans

Francesca Galbiati, Anna Aulinas, Karen Klahr Miller, John M. Davis, C Sue Carter, Ursula B. Kaiser, Rona S. Carroll, Franziska Plessow, Elizabeth A. Lawson, Stephanie B. Seminara, Mark Campbell, Lacey Plummer, Shawn Nazarloo
article en
1 citations

Abstract

Arginine-vasopressin (AVP) deficiency (AVP-D) is caused by hypothalamic-pituitary damage of vasopressinergic neurons leading to polyuria and polydipsia. Diagnostic tests for AVP-D are limited by low accuracy and/or tolerability. Kisspeptin (KP) stimulates AVP release in animals, but no study has investigated KP as a provocative test for AVP-D in humans. We investigated circulating AVP levels in response to intravenous (IV) KP in adults. We also explored sex differences in AVP response to KP. Twelve healthy adults (50% female) received an IV KP bolus. Serum AVP was measured pre- and 10, 20, 40, and 60 min post-KP. AVP levels were higher in males at all time points (p = .028) and did not change in response to KP. KP did not stimulate AVP, possibly due to dose, administration route, or cross-species differences in the AVP system. Our study does not support IV KP bolus of 0.24 nmol/kg as a provocative test for AVP-D. CLINICAL TRIAL REGISTRATION: Our study was registered on ClinicalTrials.gov (NCT00914823).

Journal of NeuroendocrinologyVol. 38(1)
Universitat de Vic - Universitat Central de Catalunya (ES), Brigham and Women's Hospital (US), Harvard University (US), University of California, San Francisco (US), Hospital de Sant Pau (ES), University of Illinois Chicago (US), Massachusetts General Hospital (US), Centre for Biomedical Network Research on Rare Diseases (ES), Indiana University Bloomington (US), University of Virginia (US)
Openalex Percentile: Top 8%
Neuroendocrine regulation and behavior
2.44
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.